BIA
RGC icon

Bell Investment Advisors’s Regencell Bioscience RGC Stock Holding History

Bell Investment Advisors’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122 Hold
20
– – ﹤0.01% 1808
2026
Q1 		$509 Buy
+20
New +$566 ﹤0.01% 1740

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Amundi
Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Bell Investment Advisors's RGC Position: Q2 2026 in Review

Bell Investment Advisors held its Regencell Bioscience (RGC) position steady in Q2 2026 at 20 shares worth $122. The position accounts for ﹤0.01% of the portfolio, ranked #1808.

Bell Investment Advisors first reported a position in RGC in Q1 2026 and has held it in 2 quarters since. The position peaked at $509 in Q1 2026. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

  • Bell Investment Advisors held 20 shares of Regencell Bioscience worth $122 as of Q2 2026.
  • Bell Investment Advisors left its Regencell Bioscience share count unchanged in Q2 2026.
  • Regencell Bioscience made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1808 holding.
  • Bell Investment Advisors first reported a position in Regencell Bioscience in Q1 2026 and has held it in 2 quarters since.
  • Bell Investment Advisors's Regencell Bioscience position peaked at $509 in Q1 2026.
  • 35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.